Related Experiment Video
Updated: Apr 29, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
11.7K
Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy
Drug Metabolism and Drug Interactions
|May 15, 2014
Summary
Understanding genetic variations in CYP2C9 is crucial for personalized medicine. This review updates functional information on CYP2C9 alleles, aiding clinical applications of pharmacogenomics.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Molecular Biology
Background:
- CYP2C9 is vital for metabolizing 20% of common drugs, including warfarin and phenytoin.
- Over 16,000 CYP2C9 variants exist, with CYP2C9*2 and CYP2C9*3 being well-studied.
- Clinical application of CYP2C9 pharmacogenomics is hindered by limited knowledge of variant functions.
Purpose of the Study:
- To review and update functional information on known and novel CYP2C9 genetic variants.
- To bridge the gap between the increasing number of genetic variants and their molecular mechanisms.
- To aid in the clinical implementation of CYP2C9 pharmacogenomics.
Main Methods:
- In silico analyses to predict functional changes of CYP2C9 alleles.
- Comparison of predicted data with existing in vitro and in vivo experimental evidence.
- Summarization of functional data for recently reported CYP2C9 variants.
Main Results:
- Functional impacts of numerous CYP2C9 alleles were predicted and compared with experimental data.
- Updated functional information for previously known CYP2C9 variants was compiled.
- A comprehensive overview of genetic variant functionalities was provided.
Conclusions:
- Accurate functional prediction and updated data are essential for understanding CYP2C9 variability.
- This review consolidates knowledge on CYP2C9 variants, supporting personalized drug therapy.
- Further research into the molecular mechanisms of CYP2C9 variants will enhance pharmacogenomic applications.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:16Drug toxicity: Idiosyncratic Reactions
220
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
220
01:27Principles of Pharmacogenetics: Types of Genetic Variants
137
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
137